Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PHAT 
Phathom Pharmaceuticals Inc (PHAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: PHAT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19.88
1 Year Target Price $19.88
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.16% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 617.85M USD | Price to earnings Ratio - | 1Y Target Price 19.88 |
Price to earnings Ratio - | 1Y Target Price 19.88 | ||
Volume (30-day avg) 9 | Beta 0.1 | 52 Weeks Range 2.21 - 19.71 | Updated Date 07/2/2025 |
52 Weeks Range 2.21 - 19.71 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -276.53% |
Management Effectiveness
Return on Assets (TTM) -55.01% | Return on Equity (TTM) -3489% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 609100970 | Price to Sales(TTM) 7.55 |
Enterprise Value 609100970 | Price to Sales(TTM) 7.55 | ||
Enterprise Value to Revenue 7.44 | Enterprise Value to EBITDA -2.2 | Shares Outstanding 69814096 | Shares Floating 54978605 |
Shares Outstanding 69814096 | Shares Floating 54978605 | ||
Percent Insiders 4.28 | Percent Institutions 84.72 |
Upturn AI SWOT
Phathom Pharmaceuticals Inc
Company Overview
History and Background
Phathom Pharmaceuticals, Inc. was founded in 2018. It focuses on developing and commercializing treatments for gastrointestinal diseases. Key milestones include the acquisition of vonoprazan rights and FDA approval of VOQUEZNA.
Core Business Areas
- Gastrointestinal Therapeutics: Focuses on developing and commercializing treatments for acid-related GI diseases. This includes VOQUEZNA (vonoprazan) and its combination therapies.
Leadership and Structure
The company has a management team headed by CEO, Mike Royal. The organizational structure is typical of a biopharmaceutical company, with departments focused on R&D, commercialization, and operations.
Top Products and Market Share
Key Offerings
- VOQUEZNA (vonoprazan): A potassium-competitive acid blocker (PCAB) approved for the treatment of erosive esophagitis and *Helicobacter pylori* infection. Market share is growing but still relatively small. Competitors include proton pump inhibitors (PPIs) like omeprazole, esomeprazole, and lansoprazole, manufactured by companies such as AstraZeneca (AZN), Takeda (TAK), and others.
- VOQUEZNA TRIPLE PAK and DUAL PAK: Combination therapies including vonoprazan approved for the treatment of *H. pylori* infection. Competitors include standard triple and quadruple therapies containing PPIs and antibiotics.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically in the gastrointestinal therapeutic area, is competitive and constantly evolving. New drugs and formulations are continuously being developed. The market is driven by the prevalence of acid-related diseases like GERD and *H. pylori* infection.
Positioning
Phathom is positioned as an innovator with VOQUEZNA, aiming to capture market share from established PPIs by offering a potentially more effective and faster-acting alternative. The company seeks to be the leader in PCAB therapies.
Total Addressable Market (TAM)
The global GERD market is estimated to be billions of dollars annually. Phathom's positioning with VOQUEZNA is to capture a portion of this market by providing potentially superior efficacy and onset of action. Exact TAM estimates and PHAT's portion varies based on projected penetration.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (PCAB)
- FDA-approved product (VOQUEZNA)
- Potential for improved efficacy compared to PPIs
- Strong intellectual property protection
Weaknesses
- Limited commercial history
- Reliance on a single product
- High marketing expenses
- Significant debt
Opportunities
- Expansion into new indications (e.g., other acid-related diseases)
- Partnerships with other pharmaceutical companies
- Geographic expansion
- Clinical trials exploring novel uses of vonoprazan
Threats
- Competition from established PPIs
- Generic entry of PPIs
- Regulatory hurdles
- Reimbursement challenges
- Adverse events
Competitors and Market Share
Key Competitors
- AZN
- TAK
- RDY
Competitive Landscape
Phathom's advantage lies in VOQUEZNA's novel mechanism of action. Disadvantages include limited resources and a smaller sales force compared to established competitors. Phathom's product is novel but in a very mature market.
Growth Trajectory and Initiatives
Historical Growth: The company has shown growth in revenue since the launch of VOQUEZNA, driven by increased sales and market penetration.
Future Projections: Future growth is projected to continue as VOQUEZNA gains wider acceptance and market share. Analyst estimates suggest continued revenue growth but also ongoing losses in the near term.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts, and conducting clinical trials to explore new indications for VOQUEZNA.
Summary
Phathom Pharmaceuticals is a promising biopharmaceutical company with a novel product, VOQUEZNA. The company faces challenges in a competitive market and relies heavily on the success of VOQUEZNA. While the product holds potential, it requires strong marketing and sales execution, as well as additional indications and careful management of high debt. Future growth depends on successful market penetration and commercialization of VOQUEZNA and its related therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Phathom Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-10-25 | CEO, President & Director Mr. Steven L. Basta M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 427 | Website https://www.phathompharma.com |
Full time employees 427 | Website https://www.phathompharma.com | ||
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.